In this video, Dr. Dietrich Stephan, PhD, co-founder of Navigenics, talks about the ways genetic testing and personalized treatments can actually lower costs for payers and patients.
In this video, Dr. Dietrich Stephan, PhD, co-founder of Navigenics, talks about the ways genetic testing and personalized treatments can lower costs for payers and patients.
This video was taken at CBI's 4th Annual Forum for Payers on Personalized Medicine conference in Washington, DC, on March 13, 2012.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More